Plain-English translation of NCT06481904 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes research guide →This is a long-term safety study that tracks people with Stage 2 type 1 diabetes — an early stage of the disease before symptoms develop. Researchers want to learn more about how teplizumab-mzwv (TZIELD®), a recently FDA-approved medication, works over time and whether it's safe to use. The study compares people who receive this medication with people who choose not to take it.
Stage 2 type 1 diabetes is a critical window when the disease is progressing but before people need insulin. This medication has been approved to delay that progression, but doctors and patients need real-world information about how safe and effective it truly is over the long term.
You likely qualify if…
You likely don't qualify if…
You'll be part of a registry that collects information about your health over time. If you're in the treatment group, you'll receive the medication according to its standard dosing schedule (a 14-day course that gradually increases the dose). Both groups will share medical information and health updates with researchers so they can track how the disease progresses and monitor for any long-term safety concerns.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States